UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 18, 2022
 
ADMA BIOLOGICS, INC.
(Exact Name of Registrant as Specified in its Charter)

Delaware
001-36728
56-2590442
(State or Other Juris- diction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
 
465 State Route 17
Ramsey, New Jersey
  
07446
(Address of Principal Executive Offices)
  
(Zip Code)

Registrant’s telephone number, including area code: (201) 478-5552
 
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which registered
Common Stock, $0.0001 par value
  
ADMA
  
Nasdaq Global Market
Preferred Stock Purchase Rights
  
-
  
Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section

13(a) of the Exchange Act. ☐

Item 8.01
Other Events.

On January 18, 2022, ADMA Biologics, Inc. (the “Company”) issued a press release announcing that it has received U.S. Food and Drug Administration approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, SC. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d)
Exhibits
 
See the Exhibit Index below, which is incorporated by reference herein.
 
EXHIBIT INDEX
 
Exhibit Number
Description
   
Press release of ADMA Biologics, Inc. dated January 18, 2022
   
104
Cover Page Interactive Data File (embedded with the Inline XBRL document)

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
ADMA BIOLOGICS, INC.
   
 Date: January 18, 2022
By:
/s/ Brian Lenz
   
Brian Lenz
   
Executive Vice President and Chief Financial Officer